世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

インフルエンザワクチンの世界市場:価数別(4価・3価)、ワクチンタイプ別(不活化・弱毒化)、技術別(卵ベース・細胞ベース)、年齢層別(成人・小児)、投与経路別(注射・点鼻)、流通チャネル別(病院・薬局、政府・機関、その他)、地域別(COVID-19の影響と2028年までの予測)、規模・動向分析


Global Influenza Vaccine Market: Analysis by Valency (Quadrivalent & Trivalent), By Vaccine Type (Inactivated And Live Attenuated), By Technology (Egg-based & Cell-based), By Age Group (Adult & Pediatric), By Route Of Administration (Injection & Nasal Spray), By Distribution Channel (Hospitals And Pharmacy, Government And Institutions And Others), By Region Size And Trends With Impact Of COVID-19 And Forecast Up To 2028

インフルエンザワクチンは、しばしばインフルエンザワクチンと呼ばれ、インフルエンザウイルスによって引き起こされる伝染性の呼吸器疾患であるインフルエンザの蔓延と影響を軽減することを目的とした予防医学の... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Daedal Research
デダルリサーチ
2023年9月29日 US$2,350
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
165 英語

 

サマリー

インフルエンザワクチンは、しばしばインフルエンザワクチンと呼ばれ、インフルエンザウイルスによって引き起こされる伝染性の呼吸器疾患であるインフルエンザの蔓延と影響を軽減することを目的とした予防医学の分野における重要な手段である。近年、インフルエンザワクチンの需要が高まっている理由のひとつは、伝染性の呼吸器疾患の予防におけるワクチン接種の重要性に対する認識が高まっていることであり、特にCOVID-19のような世界的な大流行をきっかけに、公衆衛生におけるワクチン接種の重要性が浮き彫りになりました。季節性インフルエンザ(インフル)は、リスクの高い集団において高い入院率と死亡率をもたらし、世界的に大きな医療負担をもたらす。そのため、インフルエンザワクチン市場にはニーズがあり、大きな市場機会となっている。2022年の世界のインフルエンザワクチン市場は79.8億米ドルで、2028年には123.2億米ドルに達する見込みである。

世界全体では、インフルエンザ感染により毎年300万~500万人の重症患者と29万~65万人の死者が出ている。インフルエンザ・ワクチンの需要増加の要因としては、高齢者人口の増加、政府の支援、急速な都市化、インフルエンザの流行や季節的アウトブレイクの増加、公衆衛生意識、研究開発への積極的な投資などが挙げられる。世界各国政府は、世界保健機関(WHO)などの国際保健機関と協力して、公衆衛生と疾病予防におけるインフルエンザ・ワクチン接種の重要な役割を認識している。その結果、市場の拡大を促進するさまざまな戦略を実施している。WHOは、ワクチンを助成したり、公衆衛生プログラムを通じて無料で提供したりすることで、一般の人々にとってワクチン接種をより身近なものにし、インフルエンザ・ワクチン市場の成長につなげている。今後数年間で、こうした改善により医療サービスが大幅に向上し、インフルエンザ・ワクチンの需要が刺激されると予想される。世界のインフルエンザワクチン市場価値は、2023〜2028年の予測期間中にCAGR 7.50%で成長すると予測されている。

市場細分化分析:

価数別:報告書によると、世界のインフルエンザワクチン市場は価数によって2つのセグメントに区分される:4価と3価である。4価ワクチンは、4つのインフルエンザウイルス株(2つのインフルエンザA株と2つのインフルエンザB株)に対する予防効果があるため、2022年の市場シェアの大半を占め、最も急成長しているセグメントである。4価ワクチンの需要は、公衆衛生上の推奨やインフルエンザの深刻さに対する意識の高まりなどの要因により、近年増加している。

ワクチンタイプ別:報告書によると、世界のインフルエンザワクチン市場は2つのタイプに二分される:不活化ワクチンと弱毒化ワクチンである。不活化ワクチンは、死滅したインフルエンザウイルスまたはウイルスの一部から作られ、注射によって投与されるため、2022年の市場シェアは不活化ワクチンが過半数を占め、最も急成長している。投与方法として注射が便利であること、複数の製造業者が利用可能であることが、広く使用される要因となっている。さらに、安全性と有効性が確立されていること、一般市民の意識向上キャンペーンやパンデミック対策への取り組みが、インフルエンザ・ワクチン市場における不活化ワクチンの成長に寄与している。

技術別:報告書によると、世界のインフルエンザワクチン市場は2つの技術に二分される:卵ベースと細胞ベースである。卵ベースのセグメントは、その長年にわたって確立されたインフラ、実証された安全性と有効性、大規模生産能力により、2022年の市場で大半のシェアを獲得した。しかし、細胞培養に基づくインフルエンザワクチン製造は鶏卵を必要とせず、インフルエンザワクチン製造プロセスの迅速な立ち上げが可能であるため、細胞培養技術は最も急成長している分野である。2016年8月31日には、米国で唯一のFDA認可細胞培養ベースのインフルエンザワクチン製造業者であるSequirusが、細胞培養で育ったCVVの使用を開始する認可をFDAが下している。

年齢層別報告書によると、世界のインフルエンザワクチン市場は2つの年齢層に二分される:成人と小児科である。成人はほとんどの地域で人口動態全体のかなりの部分を占めており、成人はインフルエンザ合併症のリスクが高い。さらに、労働力として働く成人は、健康だけでなく経済的生産性を維持するためにも極めて重要なターゲットであり、雇用主はワクチン接種を奨励している。これらの要因が相まって、成人用インフルエンザワクチンは、インフルエンザワクチン市場における年齢層別の主要シェアを維持している。一方、小児のインフルエンザ・ウイルス感染者数が増加しており、保護者の意識も高まっていることから、予測期間中、小児セグメントが最も速い成長率を記録すると予想される。また、多くの国で、この年齢層を対象とした学校ベースのインフルエンザ・ワクチン接種プログラムが実施されており、教育現場でのインフルエンザ感染を減少させることが、このセグメントの成長に繋がっている。

投与経路別:報告書によると、世界のインフルエンザワクチン市場は2つの投与経路に二分される:注射と点鼻である。注射剤は、汎用性が高く、安全性が証明されており、推奨範囲が広いため、2022年には市場の大半のシェアを獲得し、最も急成長している。注射は、乳幼児から高齢者まで、また様々な健康状態にある人まで、多様な人々に適しており、普遍的な選択肢となっている。さらに、注射ベースのワクチンは広く利用され、受け入れられているため、市場で優位な地位を占め、今後数年間も成長が続く可能性がある。

流通チャネル別:報告書によると、世界のインフルエンザワクチン市場は3つの流通チャネルに二分される:病院・薬局、政府・機関、その他である。病院・薬局は、その利便性と信頼性の高い医療環境により、2022年のインフルエンザワクチン市場で大きなシェアを占めている。病院・薬局は、定期的な医療受診の際にインフルエンザワクチンを接種する場所として利用されている。看護師や薬剤師を含む訓練された医療専門家のスタッフにより、これらの機関は安全で効果的なワクチン投与を保証し、ワクチン受領者の信頼を醸成している。一方、政府機関や医療機関は、予防接種や予防接種プログラムが進行中であり、世界中の予防接種プログラムにインフルエンザワクチンが含まれていることから、予測期間中最も急成長している分野である。例えば、2022年6月、ニュージーランド政府は、小児および精神衛生上の問題を抱える人々を対象に、インフルエンザワクチンの無料接種を拡大した。

地域別本レポートでは、北米、欧州、アジア太平洋、中南米、中東・アフリカという地理的事業に基づいて、インフルエンザワクチン市場を洞察している。北米のインフルエンザワクチン市場は2022年に最も高い市場シェアを占めましたが、その主な理由は、米国およびカナダにおけるインフルエンザ感染の有病率の増加、国民の意識向上キャンペーンや教育イニシアチブの増加、政府主催のワクチン接種プログラム、規制当局の支援、高齢者や妊婦などのハイリスクグループの認識、同地域の強固な医療インフラ、保険適用、患者中心のケアの重視などです。米国は、ワクチン製造の技術的進歩に重点を置き、医療費支出が増加しているため、インフルエンザ・ワクチンの北米最強市場である。

アジア太平洋地域のインフルエンザ・ワクチン市場は、急増する多様な人口、政府の取り組み、医療意識の高まりにより、急成長が見込まれています。また、この地域は季節的流行に対して脆弱であり、過去のインフルエンザ・パンデミックやCOVIDパンデミックの記憶と相まって、ワクチン接種の重要性が強調されています。さらに、健康保険が適用され、海外旅行が増加していることも、ワクチン需要を促進すると予想される。中国がアジア太平洋地域で最大のシェアを占めているのは、高齢者人口の増加、季節性インフルエンザの流行や新型インフルエンザの出現に対する同地域の脆弱性、医療インフラの拡大、急成長する製薬産業、研究開発イニシアティブ、ワクチンの国内生産、医療産業への人工知能の導入などによる。

世界のインフルエンザワクチン市場動向:

成長の原動力:高齢者のインフルエンザ罹患率の増加は、インフルエンザワクチン市場の成長を後押しする可能性がある。高齢者はインフルエンザにかかりやすいため、インフルエンザワクチンの売上に大きく貢献するだろう。CDCによると、米国では、インフルエンザに感染した65歳以上の人々や危険因子(喘息、糖尿病、心臓病、免疫不全など)を持つ人々が重症化したり入院したりする可能性が最も高く、これは転帰の悪化や死亡の可能性につながる可能性がある(インフルエンザ関連死亡の〜85%、インフルエンザ関連入院の〜52%は65歳以上で発生している)。さらに、政府の積極的な取り組み、急速な都市化、インフルエンザの流行や季節的流行の増加、公衆衛生意識、研究開発への積極的な投資などにより、市場の拡大が見込まれている。

課題インフルエンザワクチン市場にとって、製造期間が長期化することはいくつかの課題となり得る。インフルエンザワクチンの製造スケジュールには、各シーズンのワクチンの開発、製造、流通が含まれる。複雑な臨床開発、ワクチン研究、規制要件のため、このプロセスには5〜10年を要する。臨床試験や規制当局からの製品承認における地域差は、このプロセスをさらに複雑にしている。インフルエンザ・ワクチン市場が直面するその他の課題として、ワクチンへの不公平なアクセスとワクチン開発費用の高さが挙げられる。

トレンド人工知能(AI)と機械学習は、ワクチンに最も適したウイルス株の選択、最適な免疫反応を得るための抗原設計、さらには潜在的な抗ウイルス薬の発見に役立つため、インフルエンザ・ワクチン市場の大きなトレンドとなっている。また、AIは遺伝子検査、臨床試験、研究から収集したデータをより迅速かつ効果的に活用することを可能にし、ワクチン開発期間を短縮して有効性を高める。AIは、タイムリーな流通のためのサプライチェーン管理も支援し、データ分析を通じてインフルエンザの広がりを監視し、アウトブレイクの早期発見を可能にする。予測期間中のインフルエンザ・ワクチン市場の成長は、ワクチン投与における技術的進歩、有利な政府の取り組みや政策など、市場のさらなる動向によって増大すると考えられている。

COVID-19の影響分析と今後の展望:

COVID-19パンデミックは、世界のインフルエンザワクチン市場にプラスの影響を与えました。インフルエンザウイルスとCOVID-19ウイルスは同じ症状を示し、感染経路も似ているため、ワクチン接種はCOVID-19とインフルエンザの重症化と死亡を予防するための重要な要素となった。WHOでさえ、高齢者、幼児、妊娠中の人、基礎疾患を持つ人、医療従事者にインフルエンザワクチンの接種を推奨している。COVID以降も、医療資源への負担を軽減し、COVID-19との同時感染のリスクを最小化し、公衆衛生全般の備えを強化するために、個人や医療制度がワクチン接種を優先しているため、インフルエンザ・ワクチンへの影響は持続的な成長を続けている。

競合情勢と最近の動向:

世界のインフルエンザワクチン市場は細分化されている。世界のインフルエンザワクチン市場の主要企業は以下の通り:

グラクソ・スミスクライン Plc
アボット
ファイザー
アストラゼネカ
サノフィ
モデナ社
CSLリミテッド
エマージェント・バイオソリューションズ社
株式会社ビケン
セラム・インスティテュート・オブ・インディアPvt.
シノバック
GCバイオファーマ

主要企業は、この市場での競争力を維持するため、新技術の採用や新興市場へのサービス導入など、戦略的な取り組みに絶えず投資している。例えば、2023年4月10日、Sinovac Biotech Ltd.は北京に最先端のインフルエンザワクチン製造施設を開設し、環境に配慮した製造プロセスと中国の適正製造基準ガイドラインの遵守を実現した。


ページTOPに戻る


目次

1. Executive Summary

2. Introduction

2.1 Influenza Vaccine: An Overview
2.1.1 Common Symptoms of Influenza Virus

2.2 Influenza Vaccine Segmentation: An Overview
2.2.1 Influenza Vaccine Segmentation

3. Global Market Analysis

3.1 Global Influenza Vaccine Market: An Analysis

3.1.1 Global Influenza Vaccine Market: An Overview
3.1.2 Global Influenza Vaccine Market by Value
3.1.3 Global Influenza Vaccine Market by Valency (Quadrivalent and Trivalent)
3.1.4 Global Influenza Vaccine Market by Vaccine Type (Inactivated and Live Attenuated)
3.1.5 Global Influenza Vaccine Market by Technology (Egg-Based and Cell-Based)
3.1.6 Global Influenza Vaccine Market by Age Group (Adult and Pediatric)
3.1.7 Global Influenza Vaccine Market by Route of Administration (Injection and Nasal Spray)
3.1.8 Global Influenza Vaccine Market by Distribution Channel (Hospitals and Pharmacies, Government and Institutions and Others)
3.1.9 Global Influenza Vaccine Market by Region (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

3.2 Global Influenza Vaccine Market: Valency Analysis

3.2.1 Global Influenza Vaccine Market by Valency: An Overview
3.2.2 Global Quadrivalent Influenza Vaccine Market by Value
3.2.3 Global Trivalent Influenza Vaccine Market by Value

3.3 Global Influenza Vaccine Market: Vaccine Type Analysis

3.3.1 Global Influenza Vaccine Market by Vaccine Type: An Overview
3.3.2 Global Inactivated Influenza Vaccine Market by Value
3.3.3 Global Live Attenuated Influenza Vaccine Market by Value

3.4 Global Influenza Vaccine Market: Technology Analysis

3.4.1 Global Influenza Vaccine Market by Technology: An Overview
3.4.2 Global Egg Based Influenza Vaccine Market by Value
3.4.3 Global Cell Based Influenza Vaccine Market by Value

3.5 Global Influenza Vaccine Market: Age Group Analysis

3.5.1 Global Influenza Vaccine Market by Age Group: An Overview
3.5.2 Global Adult Influenza Vaccine Market by Value
3.5.3 Global Pediatric Influenza Vaccine Market by Value

3.6 Global Influenza Vaccine Market: Route of Administration Analysis

3.6.1 Global Influenza Vaccine Market by Route of Administration: An Overview
3.6.2 Global Injectable Influenza Vaccine Market by Value
3.6.3 Global Nasal Spray Influenza Vaccine Market by Value

3.7 Global Influenza Vaccine Market: Distribution Channel Analysis

3.7.1 Global Influenza Vaccine Market by Distribution Channel: An Overview
3.7.2 Global Hospitals and Pharmacy Influenza Vaccine Market by Value
3.7.3 Global Government and Institutions Influenza Vaccine Market by Value
3.7.4 Global Others Influenza Vaccine Market by Value

4. Regional Market Analysis

4.1 North America Influenza Vaccine Market: An Analysis

4.1.1 North America Influenza Vaccine Market: An Overview
4.1.2 North America Influenza Vaccine Market by Value
4.1.3 North America Influenza Vaccine Market by Region (The US, Canada, Mexico)
4.1.4 The US Influenza Vaccine Market by Value
4.1.5 Canada Influenza Vaccine Market by Value
4.1.6 Mexico Influenza Vaccine Market by Value

4.2 Europe Influenza Vaccine Market: An Analysis

4.2.1 Europe Influenza Vaccine Market: An Overview
4.2.2 Europe Influenza Vaccine Market by Value
4.2.3 Europe Influenza Vaccine Market by Region (Germany, UK, France, Italy, Spain and Rest of Europe)
4.2.4 UK Influenza Vaccine Market by Value
4.2.5 Germany Influenza Vaccine Market by Value
4.2.6 France Influenza Vaccine Market by Value
4.2.7 Italy Influenza Vaccine Market by Value
4.2.8 Spain Influenza Vaccine Market by Value
4.2.9 Rest of Europe Influenza Vaccine Market by Value

4.3 Asia Pacific Influenza Vaccine Market: An Analysis

4.3.1 Asia Pacific Influenza Vaccine Market: An Overview
4.3.2 Asia Pacific Influenza Vaccine Market by Value
4.3.3 Asia Pacific Influenza Vaccine Market by Region (China, Japan, India, South Korea and Rest of Asia Pacific)
4.3.4 China Influenza Vaccine Market by Value
4.3.5 Japan Influenza Vaccine Market by Value
4.3.6 India Influenza Vaccine Market by Value
4.3.7 South Korea Influenza Vaccine Market by Value
4.3.8 Rest of Asia Pacific Influenza Vaccine Market by Value

4.4 Middle East & Africa Influenza Vaccine Market: An Analysis

4.4.1 Middle East & Africa Influenza Vaccine Market: An Overview
4.4.2 Middle East & Africa Influenza Vaccine Market by Value

4.5 Latin America Influenza Vaccine Market: An Analysis

4.5.1 Latin America Influenza Vaccine Market: An Overview
4.5.2 Latin America Influenza Vaccine Market by Value

5. Impact of COVID-19

5.1 Impact of COVID-19 on Influenza Vaccine Market
5.2 Post COVID-19 Impact on Influenza Vaccine Market

6. Market Dynamics

6.1 Growth Drivers
6.1.1 Increasing Flu Burden among Adult Population
6.1.2 Rapid Urbanization
6.1.3 Rising Prevalence of Influenza Epidemics and Seasonal Outbreaks
6.1.4 Increased Public Health Awareness
6.1.5 Increasing Government Support
6.1.6 Robust Research and Development Investments

6.2 Challenges
6.2.1 Longer Timeline for Vaccine Production
6.2.2 High cost of Vaccine Development
6.2.3 Inequitable Access to Vaccines

6.3 Market Trends
6.3.1 Use of AI in Vaccine Development
6.3.2 Technological Advancements in Vaccine Administration
6.3.3 Shift in Trends towards mRNA-based Flu Vaccine

7. Competitive Landscape

7.1 Global Influenza Vaccine Players by Market Share
7.2 Global Influenza Vaccine Market Players by Vaccines Efficiency and Safety
7.3 Global mRNA Influenza Vaccine Market Players by Vaccines in Clinical Development

8. Company Profiles

8.1 GlaxoSmithKline Plc
8.1.1 Business Overview
8.1.2 Sales by Products
8.1.3 Business Strategies

8.2 Abbott
8.2.1 Business Overview
8.2.2 Operating Segments
8.2.3 Business Strategies

8.3 Pfizer Inc.
8.3.1 Business Overview
8.3.2 Operating Segments
8.3.3 Business Strategies

8.4 AstraZeneca Plc
8.4.1 Business Overview
8.4.2 Revenue by Disease Area
8.4.3 Business Strategies

8.5 Sanofi S.A.
8.5.1 Business Overview
8.5.2 Operating Segments
8.5.3 Business Strategy

8.6 Moderna Inc.
8.6.1 Business Overview
8.6.2 Operating Regions
8.6.3 Business Strategies

8.7 CSL Limited
8.7.1 Business Overview
8.7.2 Operating Segments
8.7.3 Business Strategies

8.8 Emergent BioSolutions Inc
8.8.1 Business Overview
8.8.2 Operating Segments
8.8.3 Business Strategy

8.9 BIKEN Co., Ltd.
8.9.1 Business Overview
8.9.2 Business Strategy

8.10 Serum Institute of India Pvt. Ltd.
8.10.1 Business Overview
8.10.2 Business Strategy

8.11 Sinovac
8.11.1 Business Overview
8.11.2 Business Strategy

8.12 GC Biopharma
8.12.1 Business Overview
8.12.2 Business Strategy

List of Figures

Figure 1: Common Symptoms of Influenza Virus
Figure 2: Influenza Vaccine Segmentation
Figure 3: Global Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 4: Global Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 5: Global Influenza Vaccine Market by Valency; 2022 (Percentage, %)
Figure 6: Global Influenza Vaccine Market by Vaccine Type; 2022 (Percentage, %)
Figure 7: Global Influenza Vaccine Market by Technology; 2022 (Percentage, %)
Figure 8: Global Influenza Vaccine Market by Age Group; 2022 (Percentage, %)
Figure 9: Global Influenza Vaccine Market by Route of Administration; 2022 (Percentage, %)
Figure 10: Global Influenza Vaccine Market by Distribution Channel; 2022 (Percentage, %)
Figure 11: Global Influenza Vaccine Market by Region; 2022 (Percentage, %)
Figure 12: Global Quadrivalent Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 13: Global Quadrivalent Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 14: Global Trivalent Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 15: Global Trivalent Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 16: Global Inactivated Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 17: Global Inactivated Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 18: Global Live Attenuated Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 19: Global Live Attenuated Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 20: Global Egg Based Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 21: Global Egg Based Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 22: Global Cell Based Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 23: Global Cell Based Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 24: Global Adult Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 25: Global Adult Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 26: Global Pediatric Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 27: Global Pediatric Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 28: Global Injectable Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 29: Global Injectable Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 30: Global Nasal Spray Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 31: Global Nasal Spray Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 32: Global Hospitals and Pharmacy Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 33: Global Hospitals and Pharmacy Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 34: Global Government and Institutions Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 35: Global Government and Institutions Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 36: Global Others Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 37: Global Others Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 38: North America Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 39: North America Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 40: North America Influenza Vaccine Market by Region; 2022 (Percentage, %)
Figure 41: The US Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 42: The US Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 43: Canada Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 44: Canada Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 45: Mexico Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 46: Mexico Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 47: Europe Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 48: Europe Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 49: Europe Influenza Vaccine Market by Region; 2022 (Percentage, %)
Figure 50: UK Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 51: UK Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 52: Germany Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 53: Germany Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 54: France Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 55: France Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 56: Italy Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 57: Italy Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 58: Spain Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 59: Spain Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 60: Rest of Europe Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 61: Rest of Europe Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 62: Asia Pacific Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 63: Asia Pacific Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 64: Asia Pacific Influenza Vaccine Market by Region; 2022 (Percentage, %)
Figure 65: China Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 66: China Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 67: Japan Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 68: Japan Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 69: India Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 70: India Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 71: South Korea Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 72: South Korea Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 73: Rest of Asia Pacific Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 74: Rest of Asia Pacific Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 75: Middle East & Africa Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 76: Middle East & Africa Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 77: Latin America Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 78: Latin America Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 79: The US Flu Disease Burden by Age Group; 2021-2022 Flu Season (Percentage, %)
Figure 80: Global Urban Population; 2016, 2021 & 2050 (Billion)
Figure 81: Global Market Size for Artificial Intelligence in Healthcare; 2021-2030 (US $Billion)
Figure 82: Global Influenza Vaccine Players by Market Share; 2022 (Percentage, %)
Figure 83: GlaxoSmithKline Plc Sales by Products; 2022 (Percentage, %)
Figure 84: Abbott Sales by Segments; 2022 (Percentage, %)
Figure 85: Pfizer Inc. Revenue by Segment; 2022 (Percentage, %)
Figure 86: AstraZeneca Total Revenue by Disease Areas; 2022 (Percentage, %)
Figure 87: Sanofi S.A. Net Sales by Segments; 2022 (Percentage, %)
Figure 88: Moderna Inc. Total Revenue by Geographic Area; 2022 (Percentage, %)
Figure 89: CSL Limited Revenue by Segments; 2022 (Percentage, %)
Figure 90: Emergent BioSolutions Revenue by Segments; 2022 (Percentage, %)
Table 1: Global Influenza Vaccine Market Players by Vaccine Efficiency and Safety Comparison
Table 2: Global mRNA Influenza Vaccine Market Players by Vaccines in Clinical Development

 

ページTOPに戻る


 

Summary

The influenza vaccine, often referred to as the flu vaccine, is a critical tool in the field of preventive medicine aimed at reducing the spread and impact of influenza, a contagious respiratory illness caused by influenza viruses. One of the reasons leading to the rising demand for influenza vaccine in recent years is the increased awareness of the importance of vaccination in preventing contagious respiratory illnesses, especially in the wake of global pandemic like COVID-19, which has highlighted the significance of vaccination in public health. Seasonal influenza (flu) can lead to high hospitalization and mortality rates in high-risk populations, which results in significant healthcare burden globally. Thus, representing a need and large market opportunity for the influenza vaccine market. The global influenza vaccine market in 2022 stood at US$7.98 billion, and is likely to reach US$12.32 billion by 2028.

Globally, influenza infections lead to 3-5 million severe cases and 290- 650 thousand deaths annually. Some of the factors driving the rise in influenza vaccine demand include the increasing geriatric population, government support, rapid urbanization, rising prevalence of influenza epidemics and seasonal outbreaks, public health awareness, and robust research and development investments. Governments worldwide, in collaboration with international health organizations such as the World Health Organization (WHO), recognize the vital role of influenza vaccination in public health and disease prevention. As a result, they implement various strategies that foster market expansion. They may even subsidize vaccines or offer them free of charge through public health programs, making vaccination more accessible to the general population, leading to the growth of influenza vaccine market. In the coming years, these improvements are expected to significantly enhance healthcare service and stimulate demand for influenza vaccine. The global influenza vaccine market value is projected to grow at a CAGR of 7.50%, during the forecast period of 2023-2028.

Market Segmentation Analysis:

By Valency: According to the report, the global influenza vaccine market is segmented into two segments based on the valency: Quadrivalent and Trivalent. Quadrivalent segment acquired majority of share in the market in 2022 and is the fastest growing segment as well, as it provides protection against four influenza virus strains (two influenza A strains and two influenza B strains). The demand for quadrivalent vaccines has increased in recent years, driven by factors such as public health recommendations and growing awareness of the seriousness of influenza.

By Vaccine Type: According to the report, the global influenza vaccine market is bifurcated into two types: Inactivated and Live Attenuated. Inactivated segment acquired majority of share in the market in 2022 and is the fastest growing segment as well, as it is made of killed influenza viruses or parts of the viruses and is administrated through injection. The convenience of injection as an administration method and the availability of multiple manufacturers contribute to their widespread use. Furthermore, their well-established safety and effectiveness, public awareness campaigns and pandemic preparedness initiatives are collectively contributing to the growth of inactivated segment in the influenza vaccine market.

By Technology: According to the report, the global influenza vaccine market is bifurcated into two technologies: Egg-based and Cell-based. Egg-based segment acquired majority of share in the market in 2022, due to its long-established infrastructure, proven safety and efficacy, and large-scale production capabilities. Although, cell-based technology is the fastest growing segment as cell culture-based flu vaccine production does not require chicken eggs and has the potential for a faster start-up of the flu vaccine manufacturing process. Even, on August 31, 2016, FDA issued an approval for Seqirus, the sole FDA-approved cell culture-based flu vaccine manufacturer in the US, to begin using cell culture-grown CVVs.

By Age Group: According to the report, the global influenza vaccine market is bifurcated into two age group: Adults and Pediatrics. Adult segment acquired majority of share in the market in 2022 as the adult population represents a substantial portion of the overall demographic in most regions and adults are more likely to fall into high-risk influenza complications. Furthermore, Adults in the workforce are also crucial targets, not only for their health but also for maintaining economic productivity, prompting employers to encourage vaccination. These factors collectively contribute to adult influenza vaccines maintaining a major market share among age groups in the influenza vaccine market. While, the pediatric segment is expected to register the fastest growing rate during the forecasted period as there is increasing number of influenza virus cases among children and parents are becoming more aware. Even, many countries are implementing school-based influenza vaccination programs to target this age group and reduce influenza transmission in educational settings, leading to growth of this segment.

By Route of Administration: According to the report, the global influenza vaccine market is bifurcated into two routes of administration: Injection and Nasal spray. Injection segment acquired majority of share in the market in 2022 and is the fastest growing segment as well, due to its versatility, proven safety, and broad recommendations. Injections are suitable for diverse populations, spanning infants to seniors and individuals with various health conditions, making them a universal choice. Additionally, injection-based vaccines are widely available and accepted, contributing to their predominant market position and potential for continued growth in the coming years.

By Distribution Channel: According to the report, the global influenza vaccine market is bifurcated into three distribution channels: Hospitals and Pharmacies, Government and Institutions and others. Hospitals and pharmacies hold a major share in the influenza vaccine market in 2022 due to its convenience, and trusted healthcare environments. They serve as go-to locations for receiving influenza vaccines during routine healthcare visits. With their staff of trained healthcare professionals, including nurses and pharmacists, these institutions ensure safe and effective vaccine administration, fostering confidence among vaccine recipients. While, government and institutions are the fastest growing segment during forecasted period due to the ongoing vaccination and immunization programs and the inclusion of influenza vaccines in vaccination programs around the world. For instance, in June 2022, the government of New Zealand expanded access to free-of-cost flu vaccines for children and people with mental health issues.

By Region: The report provides insight into the influenza vaccine market based on the geographical operations, namely North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America influenza vaccine market held the highest market share in 2022, primarily owing to reasons such as increasing prevalence of influenza infection in the US & Canada, increasing public awareness campaigns and educational initiatives, government-sponsored vaccination programs, regulatory support, and the recognition of high-risk groups like the elderly and pregnant women, the region's robust healthcare infrastructure, insurance coverage, and emphasis on patient-centered care. The US is the North America’s strongest market for influenza vaccine because of its focus on technological advances in vaccine production, and increasing healthcare expenditure.

Asia Pacific influenza vaccine market is expected to experience fastest growth due to a burgeoning and diverse population, government initiatives and increasing healthcare awareness. Also, the region's vulnerability to seasonal outbreaks, coupled with the memory of past influenza pandemics and COVID pandemic, highlights the importance of vaccination. Furthermore, the availability of health insurance coverage and the growth of international travel further is expected to drive vaccine demand. China holds the largest share in Asia Pacific region owing the growing elderly population, region’s vulnerability to seasonal influenza outbreaks and emergence of new flu, nation's expanding healthcare infrastructure, a burgeoning pharmaceutical industry, research and development initiatives, domestic vaccine production and introduction of artificial intelligence in healthcare industry.

Global Influenza vaccine Market Dynamics:

Growth Drivers: Increasing flu Burden among old population has the potential to boost the growth of the influenza vaccine market. As older adults are more vulnerable to influenza, it will significantly contribute to the sales of influenza vaccines. According to CDC, in the US, people 65+ years of age or those with risk factors (e.g., asthma, diabetes, heart disease, immunocompromised) who are infected with the flu are the most likely to experience severe illness or be hospitalized and this could potentially lead to worse outcomes and possible deaths (~85% of flu-related deaths and ~52% of flu-related hospitalizations occur among those 65 and older.). Further, the market is expected to increase due to favorable government initiatives, rapid urbanization, rising prevalence of influenza epidemics and seasonal outbreaks, public health awareness, and robust research and development investments etc.

Challenges: Longer production timeline can present several challenges for the influenza vaccine market. Production timelines for influenza vaccines involve the development, production, and distribution of vaccines for each season. The process takes 5-10 years due to complex clinical development, vaccine research, and regulatory requirements. Regional differences in clinical trials and product approvals from regulatory bodies further complicate the process. Other challenges that influenza vaccine market faces are inequitable access to vaccines and high cost of vaccine development.

Trends: A major trend gaining pace in influenza vaccine market is Artificial Intelligence (AI) and machine learning as it assists in selecting the most appropriate virus strains for vaccines, designing antigens for optimal immune response, and even discovering potential antiviral drugs. Also, AI enables faster and more effective utilization of data collected from genetic testing, clinical trials, and research which reduces vaccine development time and increase efficacy. AI also assists in supply chain management for timely distribution and it monitors influenza spread through data analysis, enabling early outbreak detection. More trends in the market are believed to augment the growth of influenza vaccine market during the forecasted period include, technological advancements in vaccine administration, favorable government initiatives and policies, etc.

Impact Analysis of COVID-19 and Way Forward:

The COVID-19 pandemic has had positive impact on the global influenza vaccine market. Influenza virus and COVID 19 virus share same symptoms and spread in similar ways so vaccination became an important part of preventing severe disease and death for both COVID-19 and influenza. Even WHO recommended the influenza vaccine for older individuals, young children, pregnant people, people with underlying health conditions, and health workers. Post-COVID, the impact on influenza vaccine continues to drive sustained growth as individuals and healthcare systems prioritize vaccination to reduce the burden on healthcare resources, minimize the risk of co-infections with COVID-19, and enhance overall public health preparedness.

Competitive Landscape and Recent Developments:

Global Influenza vaccine market is fragmented. Key players of global Influenza vaccine market are:

GlaxoSmithKline Plc
Abbott
Pfizer Inc.
AstraZeneca Plc
Sanofi S.A.
Moderna Inc.
CSL Limited
Emergent BioSolutions Inc.
BIKEN Co., Ltd.
Serum Institute of India Pvt. Ltd.
Sinovac
GC Biopharma

The key players are constantly investing in strategic initiatives, such as adoption of new technologies, introducing their services to emerging markets and more, to maintain a competitive edge in this market. For instance, on April 10, 2023, Sinovac Biotech Ltd. opened a state-of-the-art influenza vaccine production facility in Beijing, utilizing green production processes and adherence to Chinese Good Manufacturing Practice guidelines.



ページTOPに戻る


Table of Contents

1. Executive Summary

2. Introduction

2.1 Influenza Vaccine: An Overview
2.1.1 Common Symptoms of Influenza Virus

2.2 Influenza Vaccine Segmentation: An Overview
2.2.1 Influenza Vaccine Segmentation

3. Global Market Analysis

3.1 Global Influenza Vaccine Market: An Analysis

3.1.1 Global Influenza Vaccine Market: An Overview
3.1.2 Global Influenza Vaccine Market by Value
3.1.3 Global Influenza Vaccine Market by Valency (Quadrivalent and Trivalent)
3.1.4 Global Influenza Vaccine Market by Vaccine Type (Inactivated and Live Attenuated)
3.1.5 Global Influenza Vaccine Market by Technology (Egg-Based and Cell-Based)
3.1.6 Global Influenza Vaccine Market by Age Group (Adult and Pediatric)
3.1.7 Global Influenza Vaccine Market by Route of Administration (Injection and Nasal Spray)
3.1.8 Global Influenza Vaccine Market by Distribution Channel (Hospitals and Pharmacies, Government and Institutions and Others)
3.1.9 Global Influenza Vaccine Market by Region (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

3.2 Global Influenza Vaccine Market: Valency Analysis

3.2.1 Global Influenza Vaccine Market by Valency: An Overview
3.2.2 Global Quadrivalent Influenza Vaccine Market by Value
3.2.3 Global Trivalent Influenza Vaccine Market by Value

3.3 Global Influenza Vaccine Market: Vaccine Type Analysis

3.3.1 Global Influenza Vaccine Market by Vaccine Type: An Overview
3.3.2 Global Inactivated Influenza Vaccine Market by Value
3.3.3 Global Live Attenuated Influenza Vaccine Market by Value

3.4 Global Influenza Vaccine Market: Technology Analysis

3.4.1 Global Influenza Vaccine Market by Technology: An Overview
3.4.2 Global Egg Based Influenza Vaccine Market by Value
3.4.3 Global Cell Based Influenza Vaccine Market by Value

3.5 Global Influenza Vaccine Market: Age Group Analysis

3.5.1 Global Influenza Vaccine Market by Age Group: An Overview
3.5.2 Global Adult Influenza Vaccine Market by Value
3.5.3 Global Pediatric Influenza Vaccine Market by Value

3.6 Global Influenza Vaccine Market: Route of Administration Analysis

3.6.1 Global Influenza Vaccine Market by Route of Administration: An Overview
3.6.2 Global Injectable Influenza Vaccine Market by Value
3.6.3 Global Nasal Spray Influenza Vaccine Market by Value

3.7 Global Influenza Vaccine Market: Distribution Channel Analysis

3.7.1 Global Influenza Vaccine Market by Distribution Channel: An Overview
3.7.2 Global Hospitals and Pharmacy Influenza Vaccine Market by Value
3.7.3 Global Government and Institutions Influenza Vaccine Market by Value
3.7.4 Global Others Influenza Vaccine Market by Value

4. Regional Market Analysis

4.1 North America Influenza Vaccine Market: An Analysis

4.1.1 North America Influenza Vaccine Market: An Overview
4.1.2 North America Influenza Vaccine Market by Value
4.1.3 North America Influenza Vaccine Market by Region (The US, Canada, Mexico)
4.1.4 The US Influenza Vaccine Market by Value
4.1.5 Canada Influenza Vaccine Market by Value
4.1.6 Mexico Influenza Vaccine Market by Value

4.2 Europe Influenza Vaccine Market: An Analysis

4.2.1 Europe Influenza Vaccine Market: An Overview
4.2.2 Europe Influenza Vaccine Market by Value
4.2.3 Europe Influenza Vaccine Market by Region (Germany, UK, France, Italy, Spain and Rest of Europe)
4.2.4 UK Influenza Vaccine Market by Value
4.2.5 Germany Influenza Vaccine Market by Value
4.2.6 France Influenza Vaccine Market by Value
4.2.7 Italy Influenza Vaccine Market by Value
4.2.8 Spain Influenza Vaccine Market by Value
4.2.9 Rest of Europe Influenza Vaccine Market by Value

4.3 Asia Pacific Influenza Vaccine Market: An Analysis

4.3.1 Asia Pacific Influenza Vaccine Market: An Overview
4.3.2 Asia Pacific Influenza Vaccine Market by Value
4.3.3 Asia Pacific Influenza Vaccine Market by Region (China, Japan, India, South Korea and Rest of Asia Pacific)
4.3.4 China Influenza Vaccine Market by Value
4.3.5 Japan Influenza Vaccine Market by Value
4.3.6 India Influenza Vaccine Market by Value
4.3.7 South Korea Influenza Vaccine Market by Value
4.3.8 Rest of Asia Pacific Influenza Vaccine Market by Value

4.4 Middle East & Africa Influenza Vaccine Market: An Analysis

4.4.1 Middle East & Africa Influenza Vaccine Market: An Overview
4.4.2 Middle East & Africa Influenza Vaccine Market by Value

4.5 Latin America Influenza Vaccine Market: An Analysis

4.5.1 Latin America Influenza Vaccine Market: An Overview
4.5.2 Latin America Influenza Vaccine Market by Value

5. Impact of COVID-19

5.1 Impact of COVID-19 on Influenza Vaccine Market
5.2 Post COVID-19 Impact on Influenza Vaccine Market

6. Market Dynamics

6.1 Growth Drivers
6.1.1 Increasing Flu Burden among Adult Population
6.1.2 Rapid Urbanization
6.1.3 Rising Prevalence of Influenza Epidemics and Seasonal Outbreaks
6.1.4 Increased Public Health Awareness
6.1.5 Increasing Government Support
6.1.6 Robust Research and Development Investments

6.2 Challenges
6.2.1 Longer Timeline for Vaccine Production
6.2.2 High cost of Vaccine Development
6.2.3 Inequitable Access to Vaccines

6.3 Market Trends
6.3.1 Use of AI in Vaccine Development
6.3.2 Technological Advancements in Vaccine Administration
6.3.3 Shift in Trends towards mRNA-based Flu Vaccine

7. Competitive Landscape

7.1 Global Influenza Vaccine Players by Market Share
7.2 Global Influenza Vaccine Market Players by Vaccines Efficiency and Safety
7.3 Global mRNA Influenza Vaccine Market Players by Vaccines in Clinical Development

8. Company Profiles

8.1 GlaxoSmithKline Plc
8.1.1 Business Overview
8.1.2 Sales by Products
8.1.3 Business Strategies

8.2 Abbott
8.2.1 Business Overview
8.2.2 Operating Segments
8.2.3 Business Strategies

8.3 Pfizer Inc.
8.3.1 Business Overview
8.3.2 Operating Segments
8.3.3 Business Strategies

8.4 AstraZeneca Plc
8.4.1 Business Overview
8.4.2 Revenue by Disease Area
8.4.3 Business Strategies

8.5 Sanofi S.A.
8.5.1 Business Overview
8.5.2 Operating Segments
8.5.3 Business Strategy

8.6 Moderna Inc.
8.6.1 Business Overview
8.6.2 Operating Regions
8.6.3 Business Strategies

8.7 CSL Limited
8.7.1 Business Overview
8.7.2 Operating Segments
8.7.3 Business Strategies

8.8 Emergent BioSolutions Inc
8.8.1 Business Overview
8.8.2 Operating Segments
8.8.3 Business Strategy

8.9 BIKEN Co., Ltd.
8.9.1 Business Overview
8.9.2 Business Strategy

8.10 Serum Institute of India Pvt. Ltd.
8.10.1 Business Overview
8.10.2 Business Strategy

8.11 Sinovac
8.11.1 Business Overview
8.11.2 Business Strategy

8.12 GC Biopharma
8.12.1 Business Overview
8.12.2 Business Strategy

List of Figures

Figure 1: Common Symptoms of Influenza Virus
Figure 2: Influenza Vaccine Segmentation
Figure 3: Global Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 4: Global Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 5: Global Influenza Vaccine Market by Valency; 2022 (Percentage, %)
Figure 6: Global Influenza Vaccine Market by Vaccine Type; 2022 (Percentage, %)
Figure 7: Global Influenza Vaccine Market by Technology; 2022 (Percentage, %)
Figure 8: Global Influenza Vaccine Market by Age Group; 2022 (Percentage, %)
Figure 9: Global Influenza Vaccine Market by Route of Administration; 2022 (Percentage, %)
Figure 10: Global Influenza Vaccine Market by Distribution Channel; 2022 (Percentage, %)
Figure 11: Global Influenza Vaccine Market by Region; 2022 (Percentage, %)
Figure 12: Global Quadrivalent Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 13: Global Quadrivalent Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 14: Global Trivalent Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 15: Global Trivalent Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 16: Global Inactivated Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 17: Global Inactivated Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 18: Global Live Attenuated Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 19: Global Live Attenuated Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 20: Global Egg Based Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 21: Global Egg Based Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 22: Global Cell Based Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 23: Global Cell Based Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 24: Global Adult Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 25: Global Adult Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 26: Global Pediatric Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 27: Global Pediatric Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 28: Global Injectable Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 29: Global Injectable Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 30: Global Nasal Spray Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 31: Global Nasal Spray Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 32: Global Hospitals and Pharmacy Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 33: Global Hospitals and Pharmacy Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 34: Global Government and Institutions Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 35: Global Government and Institutions Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 36: Global Others Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 37: Global Others Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 38: North America Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 39: North America Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 40: North America Influenza Vaccine Market by Region; 2022 (Percentage, %)
Figure 41: The US Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 42: The US Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 43: Canada Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 44: Canada Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 45: Mexico Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 46: Mexico Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 47: Europe Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 48: Europe Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 49: Europe Influenza Vaccine Market by Region; 2022 (Percentage, %)
Figure 50: UK Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 51: UK Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 52: Germany Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 53: Germany Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 54: France Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 55: France Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 56: Italy Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 57: Italy Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 58: Spain Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 59: Spain Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 60: Rest of Europe Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 61: Rest of Europe Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 62: Asia Pacific Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 63: Asia Pacific Influenza Vaccine Market by Value; 2023-2028 (US$ Billion)
Figure 64: Asia Pacific Influenza Vaccine Market by Region; 2022 (Percentage, %)
Figure 65: China Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 66: China Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 67: Japan Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 68: Japan Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 69: India Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 70: India Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 71: South Korea Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 72: South Korea Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 73: Rest of Asia Pacific Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 74: Rest of Asia Pacific Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 75: Middle East & Africa Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 76: Middle East & Africa Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 77: Latin America Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 78: Latin America Influenza Vaccine Market by Value; 2023-2028 (US$ Million)
Figure 79: The US Flu Disease Burden by Age Group; 2021-2022 Flu Season (Percentage, %)
Figure 80: Global Urban Population; 2016, 2021 & 2050 (Billion)
Figure 81: Global Market Size for Artificial Intelligence in Healthcare; 2021-2030 (US $Billion)
Figure 82: Global Influenza Vaccine Players by Market Share; 2022 (Percentage, %)
Figure 83: GlaxoSmithKline Plc Sales by Products; 2022 (Percentage, %)
Figure 84: Abbott Sales by Segments; 2022 (Percentage, %)
Figure 85: Pfizer Inc. Revenue by Segment; 2022 (Percentage, %)
Figure 86: AstraZeneca Total Revenue by Disease Areas; 2022 (Percentage, %)
Figure 87: Sanofi S.A. Net Sales by Segments; 2022 (Percentage, %)
Figure 88: Moderna Inc. Total Revenue by Geographic Area; 2022 (Percentage, %)
Figure 89: CSL Limited Revenue by Segments; 2022 (Percentage, %)
Figure 90: Emergent BioSolutions Revenue by Segments; 2022 (Percentage, %)
Table 1: Global Influenza Vaccine Market Players by Vaccine Efficiency and Safety Comparison
Table 2: Global mRNA Influenza Vaccine Market Players by Vaccines in Clinical Development

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

Daedal Research社のその他分野での最新刊レポート

本レポートと同じKEY WORD(administration)の最新刊レポート


よくあるご質問


Daedal Research社はどのような調査会社ですか?


デダルリサーチ (Daedal Research) はインドとアジアを始めとして世界の医療や医薬、ICT、エネルギー、通信、化学、交通、消費財などの様々な市場を調査対象とした市場調査報告書を出版してい... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/21 10:26

156.13 円

165.08 円

200.38 円

ページTOPに戻る